rHGH Recombinant human growth hormone GENESIS PEPTIDES

37.00

Category:

Description

rHGH
Recombinant human growth hormone

10 UI

Recombinant Human Growth Hormone – rDNA origin is human growth hormone produced by identical to the dominant form of this human pituitary growth hormone.

 

+ Description

Genesis Recombinant Human Growth Hormone – rDNA origin is human growth hormone produced by identical to the dominant form of this human pituitary growth hormone. It has a molecular weight of 22,125 daltons.

Genesis rHGH is a sterile, non-pyrogenic, white lyophilised powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection (0,3% m-Cresol).

+ Mechanism of action

Somatropin (as well as endogenous HGH) binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by IGF-I produced in the liver and also locally (e.g., skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (e.g., lipolysis).

  • Tissue Growth
  • Skeletal Growth
  • Cell Growth
  • Organ Growth
  • Protein Metabolism
  • Carbohydrate Metabolism
  • Lipid Metabolism
  • Mineral Metabolism
  • Connective Tissue Metabolism
+ Adverse reaction

The list presents the most serious and/or most frequently observed adverse reactions during treatment with somatropin:

  • Sudden death in paediatric patients with Prader-Willi syndrome with risk factors including severe obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection.
  • Intracranial tumours, in particular meningiomas, in teenagers/young adults treated with radiation to the head as children for a first neoplasm and somatropin.
  • Glucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes mellitus.
  • Intracranial hypertension.
  • Significant diabetic retinopathy.
  • Slipped capital femoral epiphysis in paediatric patients.
  • Progression of preexisting scoliosis in paediatric patiens.
  • Fluid retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paraesthesias.
  • Unmasking of latent central hypothyroidism.
  • Injection site reactions/rashes and lipoatrophy (as well as rare generalized hypersensitivity reactions).
  • Pancreatitis.
+ Instructions for reconstitution

The injection is given into the sub-cutaneous layer which includes adipose tissue (fat).

alt text

If you are using insulin syringes which have short needles, you will need to enter the skin at 90°. to the skin, otherwise you can inject as shown in the illustration above with a 29 or 30 gauge, 0.5″ needle.

+ Dosage

Recommended dosage of rHGH: 2-4 IU once per day.

+ Storage
  • This product can be used not more than 3 years from the production date (see box).
  • After reconstitution, may be stored for a maximum of 14 days in a refrigerator at 2°C – 8°C.
  • Store vials in an upright position.
  • Store in a refrigerator (2°C – 8°C). Keep in the outer carton in order to protect from light.
  • For one month can be stored at room temperature.